In this regard, it is important to highlight that several phase II clinical trials are investigating HIF-1 inhibitors (such as LBH589, SCH66336, echinomycin, and 2ME2) for various cancers, including ovarian, breast, and colorectal cancers. Here, HIF1A is linked to colorectal cancer.